Parkside Financial Bank & Trust Has $877,000 Stake in Danaher Co. (NYSE:DHR)

Parkside Financial Bank & Trust raised its position in Danaher Co. (NYSE:DHR) by 23.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,791 shares of the conglomerate’s stock after purchasing an additional 711 shares during the period. Parkside Financial Bank & Trust’s holdings in Danaher were worth $877,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the stock. Marks Group Wealth Management Inc increased its stake in Danaher by 7.5% during the 4th quarter. Marks Group Wealth Management Inc now owns 3,971 shares of the conglomerate’s stock valued at $919,000 after purchasing an additional 276 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Danaher by 761.5% in the 4th quarter. Larson Financial Group LLC now owns 2,481 shares of the conglomerate’s stock worth $574,000 after acquiring an additional 2,193 shares in the last quarter. RWA Wealth Partners LLC grew its stake in shares of Danaher by 81.9% in the 4th quarter. RWA Wealth Partners LLC now owns 10,859 shares of the conglomerate’s stock worth $2,512,000 after acquiring an additional 4,888 shares in the last quarter. Townsend Asset Management Corp NC ADV grew its stake in shares of Danaher by 2.9% in the 4th quarter. Townsend Asset Management Corp NC ADV now owns 17,844 shares of the conglomerate’s stock worth $4,128,000 after acquiring an additional 510 shares in the last quarter. Finally, Lee Danner & Bass Inc. boosted its holdings in shares of Danaher by 138.5% in the 4th quarter. Lee Danner & Bass Inc. now owns 8,238 shares of the conglomerate’s stock worth $1,906,000 after buying an additional 4,784 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR traded up $17.90 during trading hours on Tuesday, hitting $253.98. 4,130,101 shares of the company’s stock traded hands, compared to its average volume of 2,740,815. The business’s fifty day moving average price is $248.72 and its two-hundred day moving average price is $230.39. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $188.08 billion, a P/E ratio of 39.46, a P/E/G ratio of 3.95 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the company earned $2.87 earnings per share. The firm’s revenue was down 10.2% on a year-over-year basis. Equities research analysts predict that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Insiders Place Their Bets

In related news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 in the last ninety days. 10.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Barclays raised their price objective on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 10th. Citigroup raised their price objective on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. KeyCorp raised their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and raised their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.